血浆代谢组学反映慢性血栓栓塞性肺动脉高压治疗反应
本研究对慢性血栓栓塞性肺动脉高压(CTEPH)患者血浆进行非靶向代谢组学分析,并与健康对照及疾病对照比较,评估肺动脉内膜剥脱术(PEA)后的代谢变化。12种代谢物可区分CTEPH与健康对照(AUC 0.64-0.94,均p<2×10-5)及疾病对照(AUC 0.58-0.77,均p<0.05),部分代谢紊乱经PEA后显著纠正(15-100%),代谢梯度提示心肺组织代谢参与。
要点
- 12种血浆代谢物可区分CTEPH与健康及疾病对照。
- 多数代谢改变与特发性肺动脉高压(IPAH)相似,仅5种代谢物可鉴别。
- PEA术后部分代谢物紊乱显著纠正,或可作无创疗效标志物。
核心结论
- CTEPH患者存在可定义并验证的血浆代谢轮廓,可区别于健康对照和疾病对照。
- 多数代谢改变与IPAH相似,仅5种代谢物可区分CTEPH与慢性血栓栓塞性疾病或IPAH。
- 部分代谢物紊乱经PEA后显著纠正,响应PEA的代谢物或可作为未来靶向治疗的无创标志物。
研究设计与样本
- 对CTEPH患者与健康对照及疾病对照进行血浆代谢物非靶向分析。
- 评估PEA前后代谢谱变化,并对部分患者在三处解剖位置采样计算血浆代谢物梯度。
主要发现
- 12种代谢物经ROC分析确认可区分CTEPH与健康对照(AUC 0.64-0.94,均p<2×10-5)及疾病对照(AUC 0.58-0.77,均p<0.05)。
- 5种代谢物(5-甲硫腺苷、N1-甲基腺苷、N1-甲基肌苷、7-甲基鸟嘌呤、N-甲酰甲硫氨酸)可区分CTEPH与慢性血栓栓塞性疾病或IPAH。
- 部分代谢物经PEA后出现显著纠正(15-100%的紊乱),但并非所有代谢物均如此。
- 解剖采样鉴定出188种血浆代谢物,在色氨酸、鞘磷脂、甲硫氨酸及三羧酸循环代谢物中见显著梯度。
- 与CTEPH相关的代谢物及梯度与疾病严重程度的临床指标显著相关。
关键数值与推荐
- 12种代谢物区分CTEPH与健康对照的AUC为0.64-0.94(均p<2×10-5)。
- 12种代谢物区分CTEPH与疾病对照的AUC为0.58-0.77(均p<0.05)。
- 5种代谢物可区分CTEPH与慢性血栓栓塞性疾病或IPAH。
- PEA术后部分代谢物紊乱纠正幅度为15-100%。
- 解剖采样鉴定出188种血浆代谢物并见显著梯度。
临床怎么用
- 血浆代谢组学或可辅助CTEPH的无创诊断与鉴别诊断。
- 响应PEA的代谢物有望作为评估未来靶向治疗疗效的非侵入性标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary hypertension is a condition with limited effective treatment options. Chronic thromboembolic pulmonary hypertension (CTEPH) is a notable exception, with pulmonary endarterectomy (PEA) often proving curative. This study investigated the plasma metabolome of CTEPH patients, estimated reversibility to an effective treatment and explored the source of metabolic perturbations.We performed untargeted analysis of plasma metabolites in CTEPH patients compared to healthy controls and disease comparators. Changes in metabolic profile were evaluated in response to PEA. A subset of patients were sampled at three anatomical locations and plasma metabolite gradients calculated.We defined and validated altered plasma metabolite profiles in patients with CTEPH. 12 metabolites were confirmed by receiver operating characteristic analysis to distinguish CTEPH and both healthy (area under the curve (AUC) 0.64-0.94, all p<2×10-5) and disease controls (AUC 0.58-0.77, all p<0.05). Many of the metabolic changes were notably similar to those observed in idiopathic pulmonary arterial hypertension (IPAH). Only five metabolites (5-methylthioadenosine, N1-methyladenosine, N1-methylinosine, 7-methylguanine, N-formylmethionine) distinguished CTEPH from chronic thromboembolic disease or IPAH. Significant corrections (15-100% of perturbation) in response to PEA were observed in some, but not all metabolites. Anatomical sampling identified 188 plasma metabolites, with significant gradients in tryptophan, sphingomyelin, methionine and Krebs cycle metabolites. In addition, metabolites associated with CTEPH and gradients showed significant associations with clinical measures of disease severity.We identified a specific metabolic profile that distinguishes CTEPH from controls and disease comparators, despite the observation that most metabolic changes were common to both CTEPH and IPAH patients. Plasma metabolite gradients implicate cardiopulmonary tissue metabolism of metabolites associated with pulmonary hypertension and metabolites that respond to PEA surgery could be a suitable noninvasive marker for evaluating future targeted therapeutic interventions.
引用
- Swietlik EM, Ghataorhe P, Zalewska KI, et al. Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2021. PMID: 33060150. doi:10.1183/13993003.03201-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。